Genetics

NewLink Genetics (NASDAQ:NLNK), today reported initial data from NLG2105, a Phase 1 study evaluating indoximod, its IDO pathway inhibitor, in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors during the “Multimodality Immuno-oncology Approaches” session at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago. As quoted in the press …

NewLink Genetics (NASDAQ:NLNK), today reported initial data from NLG2105, a Phase 1 study evaluating indoximod, its IDO pathway inhibitor, in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors during the “Multimodality Immuno-oncology Approaches” session at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago.

As quoted in the press release:

Once initial safety data were generated, an additional pilot cohort of newly-diagnosed patients with diffuse intrinsic pontine glioma (DIPG) was opened using indoximod during front-line radiotherapy (RT) followed by maintenance indoximod plus temozolomide. Six newly diagnosed DIPG patients initiated treatment, with all 6 having completed induction radioimmunotherapy. Treatment was well tolerated with symptomatic improvement in all 6 patients. Site-reported radiographic review indicated near resolution of tumor in one patient at the end of radiotherapy and observable improvement in 5 out of 6 patients overall. A seventh patient with progressive DIPG received re-RT combined with indoximod, which was well tolerated with symptomatic improvement and objective tumor reduction per site-reported assessment on post-RT MRI.

“These initial findings further support the potential for indoximod in combination with other agents,” said Charles J. Link, Jr., M.D., Chairman and Chief Executive Officer. “We look forward to working with our investigators toward gathering more data on the effects of indoximod on this deadly disease.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21224.25-50.32
TSXV895.91+5.05
DOW35305.16-63.31
S&P 5004574.48-2.63
NASD14489.39-17.51
ASX7408.80-8.50

COMMODITIES

Commodities
Gold1840.05+25.98
Silver24.02+0.56
Copper4.47+0.09
Palladium2007.37+121.36
Platinum1034.99+53.99
Oil87.27+1.84
Heating Oil2.65+0.03
Natural Gas4.13-0.15

DOWNLOAD FREE REPORTS

×